Effect of Empagliflozin on Left Ventricular Mass in Patients with Type 2 Diabetes and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial

24-Hour Blood Pressure-Lowering Effect of an SGLT-2 Inhibitor in Patients with Diabetes and Uncontrolled Nocturnal Hypertension: Results from the Randomized, Placebo-Controlled SACRA Study

(2019) Kazuomi Kario et al.   CIRCULATION

Empagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Left Ventricular Hypertrophy: A Subanalysis of the EMPA-REG OUTCOME Trial

(2019) Subodh Verma et al.   DIABETES CARE

Effects of Canagliflozin on Heart Failure Outcomes Associated with Preserved and Reduced Ejection Fraction in Type 2 Diabetes: Results from the CANVAS Program

(2019) Gemma A. Figtree et al.   CIRCULATION

Dapagliflozin and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Prior Myocardial Infarction: A Sub-analysis From DECLARE TIMI-58 Trial

(2019) Remo H. M. Furtado et al.   CIRCULATION

The Serendipitous Story of SGLT2 Inhibitors in Heart Failure: New Insights from DECLARE-TIMI 58

(2019) Subodh Verma et al.   CIRCULATION

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

(2019) Vlado Perkovic et al.   NEW ENGLAND JOURNAL OF MEDICINE

Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME® randomised trial

(2018) Subodh Verma et al.   DIABETOLOGIA

SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review

(2018) Subodh Verma et al.   DIABETOLOGIA

LV Mass Independently Predicts Mortality and Need for Future Revascularization in Patients Undergoing Diagnostic Coronary Angiography

(2018) Ahmed Abdi-Ali et al.   JACC-Cardiovascular Imaging

Cardiovascular magnetic resonance of cardiac morphology and function: impact of different strategies of contour drawing and indexing

(2018) Johannes H. Riffel et al.   Clinical Research in Cardiology

Potential mechanisms underlying the cardiovascular benefits of sodium glucose cotransporter 2 inhibitors: a systematic review of data from preclinical studies

(2018) Ken Lee Chin et al.   CARDIOVASCULAR RESEARCH

Can We DECLARE a Victory against Cardio-Renal Disease in Diabetes?

(2018) Kim A. Connelly et al.   Cell Metabolism

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

(2018) Stephen D. Wiviott et al.   NEW ENGLAND JOURNAL OF MEDICINE

The effect of sacubitril/valsartan compared to olmesartan on cardiovascular remodelling in subjects with essential hypertension: the results of a randomized, double-blind, active-controlled study

(2017) Roland E Schmieder et al.   EUROPEAN HEART JOURNAL

Effects of Canagliflozin on Cardiovascular Biomarkers in Older Adults With Type 2 Diabetes

(2017) James L. Januzzi et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Real role of β-blockers in regression of left ventricular mass in hypertension patients

(2017) FuWei Xing et al.   MEDICINE

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

(2017) Bruce Neal et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Metabolodiuretic Promise of Sodium-Dependent Glucose Cotransporter 2 Inhibition

(2017) Subodh Verma et al.   JAMA Cardiology

Cardiovascular Outcomes and Safety of Empagliflozin in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease

(2017) Subodh Verma et al.   CIRCULATION

Empagliflozin’s Fuel Hypothesis: Not so Soon

(2016) Gary D. Lopaschuk et al.   Cell Metabolism

Effect of Empagliflozin on Left Ventricular Mass and Diastolic Function in Individuals With Diabetes: An Important Clue to the EMPA-REG OUTCOME Trial?

(2016) Subodh Verma et al.   DIABETES CARE

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

(2015) Bernard Zinman et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Relationship of Left Ventricular Mass and Geometry to Incident Cardiovascular Events

(2008) David A. Bluemke et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY